|
1
|
Haga IR, Shih BB, Tore G, Polo N, Ribeca P, Gombo-Ochir D, Shura G, Tserenchimed T, Enkhbold B, Purevtseren D, Ulziibat G, Damdinjav B, Yimer L, Bari FD, Gizaw D, Adedeji AJ, Atai RB, Adole JA, Dogonyaro BB, Kumarawadu PL, Batten C, Corla A, Freimanis GL, Tennakoon C, Law A, Lycett S, Downing T, Beard PM. Sequencing and Analysis of Lumpy Skin Disease Virus Whole Genomes Reveals a New Viral Subgroup in West and Central Africa. Viruses 2024; 16:557. [PMID: 38675899 PMCID: PMC11053774 DOI: 10.3390/v16040557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2023] [Revised: 03/02/2024] [Accepted: 03/05/2024] [Indexed: 04/28/2024] Open
Abstract
Lumpy skin disease virus (LSDV) is a member of the capripoxvirus (CPPV) genus of the Poxviridae family. LSDV is a rapidly emerging, high-consequence pathogen of cattle, recently spreading from Africa and the Middle East into Europe and Asia. We have sequenced the whole genome of historical LSDV isolates from the Pirbright Institute virus archive, and field isolates from recent disease outbreaks in Sri Lanka, Mongolia, Nigeria and Ethiopia. These genome sequences were compared to published genomes and classified into different subgroups. Two subgroups contained vaccine or vaccine-like samples ("Neethling-like" clade 1.1 and "Kenya-like" subgroup, clade 1.2.2). One subgroup was associated with outbreaks of LSD in the Middle East/Europe (clade 1.2.1) and a previously unreported subgroup originated from cases of LSD in west and central Africa (clade 1.2.3). Isolates were also identified that contained a mix of genes from both wildtype and vaccine samples (vaccine-like recombinants, grouped in clade 2). Whole genome sequencing and analysis of LSDV strains isolated from different regions of Africa, Europe and Asia have provided new knowledge of the drivers of LSDV emergence, and will inform future disease control strategies.
Collapse
Grants
- BB/R002606/1, BB/R008833/1, BB/X011038/1, BB/X011046/1, BB/CCG2250, BB/CCG1780/1, BBS/E/RL/230002C, BBS/E/RL/230002D, , BBS/E/I/00007039, /1, BB/IDG2250/1, Biotechnology and Biological Sciences Research Council
Collapse
Affiliation(s)
- Ismar R. Haga
- The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, UK; (I.R.H.); (N.P.); (P.R.); (C.B.); (G.L.F.); (C.T.); (T.D.)
| | - Barbara B. Shih
- The Roslin Institute, University of Edinburgh, Easter Bush Campus, Roslin, Midlothian EH25 9RG, UK; (B.B.S.); (A.L.); (S.L.)
- Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YW, UK
| | - Gessica Tore
- The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, UK; (I.R.H.); (N.P.); (P.R.); (C.B.); (G.L.F.); (C.T.); (T.D.)
| | - Noemi Polo
- The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, UK; (I.R.H.); (N.P.); (P.R.); (C.B.); (G.L.F.); (C.T.); (T.D.)
| | - Paolo Ribeca
- The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, UK; (I.R.H.); (N.P.); (P.R.); (C.B.); (G.L.F.); (C.T.); (T.D.)
- UK Health Security Agency, 61 Colindale Ave, London NW9 5EQ, UK
- NIHR Health Protection Research Unit in Genomics and Enabling Data, Mathematics Institute, Zeeman Builing, University of Warwick, Coventry CV4 7AL, UK
- NIHR Health Protection Research Unit in Gastrointestinal Infections, Ronald Ross Building, University of Liverpool, Liverpool L69 7BE, UK
- Biomathematics and Statistics Scotland, James Maxwell Clerk Building, Peter Guthrie Tait Road, Kings Buildings, Edinburgh EH9 3FD, UK
| | - Delgerzul Gombo-Ochir
- Laboratory of Transboundary Animal Disease Diagnosis and Surveillance, State Central Veterinary Laboratory, Zaisan, Ulaanbaatar 17024, Mongolia; (D.G.-O.); (G.S.); (T.T.); (B.E.); (D.P.); (G.U.)
| | - Gansukh Shura
- Laboratory of Transboundary Animal Disease Diagnosis and Surveillance, State Central Veterinary Laboratory, Zaisan, Ulaanbaatar 17024, Mongolia; (D.G.-O.); (G.S.); (T.T.); (B.E.); (D.P.); (G.U.)
| | - Tsagaan Tserenchimed
- Laboratory of Transboundary Animal Disease Diagnosis and Surveillance, State Central Veterinary Laboratory, Zaisan, Ulaanbaatar 17024, Mongolia; (D.G.-O.); (G.S.); (T.T.); (B.E.); (D.P.); (G.U.)
| | - Bazarragchaa Enkhbold
- Laboratory of Transboundary Animal Disease Diagnosis and Surveillance, State Central Veterinary Laboratory, Zaisan, Ulaanbaatar 17024, Mongolia; (D.G.-O.); (G.S.); (T.T.); (B.E.); (D.P.); (G.U.)
| | - Dulam Purevtseren
- Laboratory of Transboundary Animal Disease Diagnosis and Surveillance, State Central Veterinary Laboratory, Zaisan, Ulaanbaatar 17024, Mongolia; (D.G.-O.); (G.S.); (T.T.); (B.E.); (D.P.); (G.U.)
| | - Gerelmaa Ulziibat
- Laboratory of Transboundary Animal Disease Diagnosis and Surveillance, State Central Veterinary Laboratory, Zaisan, Ulaanbaatar 17024, Mongolia; (D.G.-O.); (G.S.); (T.T.); (B.E.); (D.P.); (G.U.)
| | - Batchuluun Damdinjav
- General Authority for Veterinary Service, Ministry of Food, Agriculture and Light Industry, Ulaanbaatar 13381, Mongolia;
| | - Lama Yimer
- School of Veterinary Medicine, Wollega University, Nekemte P.O. Box 395, Ethiopia;
- College of Veterinary Medicine and Agriculture, Addis Ababa University, Bishoftu P.O. Box 3434, Ethiopia;
| | - Fufa D. Bari
- College of Veterinary Medicine and Agriculture, Addis Ababa University, Bishoftu P.O. Box 3434, Ethiopia;
| | - Daniel Gizaw
- Animal Health Institute (AHI), Sebata P.O. Box 04, Ethiopia;
| | - Adeyinka Jeremy Adedeji
- National Veterinary Research Institute, Vom 930103, Nigeria; (A.J.A.); (R.B.A.); (J.A.A.); (B.B.D.)
| | - Rebecca Bitiyong Atai
- National Veterinary Research Institute, Vom 930103, Nigeria; (A.J.A.); (R.B.A.); (J.A.A.); (B.B.D.)
| | - Jolly Amoche Adole
- National Veterinary Research Institute, Vom 930103, Nigeria; (A.J.A.); (R.B.A.); (J.A.A.); (B.B.D.)
| | | | | | - Carrie Batten
- The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, UK; (I.R.H.); (N.P.); (P.R.); (C.B.); (G.L.F.); (C.T.); (T.D.)
| | - Amanda Corla
- The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, UK; (I.R.H.); (N.P.); (P.R.); (C.B.); (G.L.F.); (C.T.); (T.D.)
| | - Graham L. Freimanis
- The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, UK; (I.R.H.); (N.P.); (P.R.); (C.B.); (G.L.F.); (C.T.); (T.D.)
| | - Chandana Tennakoon
- The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, UK; (I.R.H.); (N.P.); (P.R.); (C.B.); (G.L.F.); (C.T.); (T.D.)
| | - Andy Law
- The Roslin Institute, University of Edinburgh, Easter Bush Campus, Roslin, Midlothian EH25 9RG, UK; (B.B.S.); (A.L.); (S.L.)
| | - Samantha Lycett
- The Roslin Institute, University of Edinburgh, Easter Bush Campus, Roslin, Midlothian EH25 9RG, UK; (B.B.S.); (A.L.); (S.L.)
| | - Tim Downing
- The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, UK; (I.R.H.); (N.P.); (P.R.); (C.B.); (G.L.F.); (C.T.); (T.D.)
| | - Philippa M. Beard
- The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, UK; (I.R.H.); (N.P.); (P.R.); (C.B.); (G.L.F.); (C.T.); (T.D.)
- School of Life Sciences, Keele University, Staffordshire ST5 5BG, UK
| |
Collapse
|
|
2
|
Semenov DV, Vasileva NS, Dymova MA, Mishinov SV, Savinovskaya YI, Ageenko AB, Dome AS, Zinchenko ND, Stepanov GA, Kochneva GV, Richter VA, Kuligina EV. Transcriptome Changes in Glioma Cells upon Infection with the Oncolytic Virus VV-GMCSF-Lact. Cells 2023; 12:2616. [PMID: 37998351 PMCID: PMC10670333 DOI: 10.3390/cells12222616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Revised: 10/25/2023] [Accepted: 11/09/2023] [Indexed: 11/25/2023] Open
Abstract
Oncolytic virotherapy is a rapidly evolving approach that aims to selectively kill cancer cells. We designed a promising recombinant vaccinia virus, VV-GMCSF-Lact, for the treatment of solid tumors, including glioma. We assessed how VV-GMCSF-Lact affects human cells using immortalized and patient-derived glioma cultures and a non-malignant brain cell culture. Studying transcriptome changes in cells 12 h or 24 h after VV-GMCSF-Lact infection, we detected the common activation of histone genes. Additionally, genes associated with the interferon-gamma response, NF-kappa B signaling pathway, and inflammation mediated by chemokine and cytokine signaling pathways showed increased expression. By contrast, genes involved in cell cycle progression, including spindle organization, sister chromatid segregation, and the G2/M checkpoint, were downregulated following virus infection. The upregulation of genes responsible for Golgi vesicles, protein transport, and secretion correlated with reduced sensitivity to the cytotoxic effect of VV-GMCSF-Lact. Higher expression of genes encoding proteins, which participate in the maturation of pol II nuclear transcripts and mRNA splicing, was associated with an increased sensitivity to viral cytotoxicity. Genes whose expression correlates with the sensitivity of cells to the virus are important for increasing the effectiveness of cancer virotherapy. Overall, the results highlight molecular markers, biological pathways, and gene networks influencing the response of glioma cells to VV-GMCSF-Lact.
Collapse
Affiliation(s)
- Dmitriy V. Semenov
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue, 8, 630090 Novosibirsk, Russia; (N.S.V.); (M.A.D.); (Y.I.S.); (A.B.A.); (A.S.D.); (N.D.Z.); (G.A.S.); (V.A.R.); (E.V.K.)
| | - Natalia S. Vasileva
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue, 8, 630090 Novosibirsk, Russia; (N.S.V.); (M.A.D.); (Y.I.S.); (A.B.A.); (A.S.D.); (N.D.Z.); (G.A.S.); (V.A.R.); (E.V.K.)
| | - Maya A. Dymova
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue, 8, 630090 Novosibirsk, Russia; (N.S.V.); (M.A.D.); (Y.I.S.); (A.B.A.); (A.S.D.); (N.D.Z.); (G.A.S.); (V.A.R.); (E.V.K.)
| | - Sergey V. Mishinov
- Novosibirsk Research Institute of Traumatology and Orthopedics n.a. Ya.L. Tsivyan, Department of Neurosurgery, Frunze Street, 17, 630091 Novosibirsk, Russia;
| | - Yulya I. Savinovskaya
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue, 8, 630090 Novosibirsk, Russia; (N.S.V.); (M.A.D.); (Y.I.S.); (A.B.A.); (A.S.D.); (N.D.Z.); (G.A.S.); (V.A.R.); (E.V.K.)
| | - Alisa B. Ageenko
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue, 8, 630090 Novosibirsk, Russia; (N.S.V.); (M.A.D.); (Y.I.S.); (A.B.A.); (A.S.D.); (N.D.Z.); (G.A.S.); (V.A.R.); (E.V.K.)
| | - Anton S. Dome
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue, 8, 630090 Novosibirsk, Russia; (N.S.V.); (M.A.D.); (Y.I.S.); (A.B.A.); (A.S.D.); (N.D.Z.); (G.A.S.); (V.A.R.); (E.V.K.)
| | - Nikita D. Zinchenko
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue, 8, 630090 Novosibirsk, Russia; (N.S.V.); (M.A.D.); (Y.I.S.); (A.B.A.); (A.S.D.); (N.D.Z.); (G.A.S.); (V.A.R.); (E.V.K.)
| | - Grigory A. Stepanov
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue, 8, 630090 Novosibirsk, Russia; (N.S.V.); (M.A.D.); (Y.I.S.); (A.B.A.); (A.S.D.); (N.D.Z.); (G.A.S.); (V.A.R.); (E.V.K.)
| | - Galina V. Kochneva
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, 630559 Koltsovo, Russia;
| | - Vladimir A. Richter
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue, 8, 630090 Novosibirsk, Russia; (N.S.V.); (M.A.D.); (Y.I.S.); (A.B.A.); (A.S.D.); (N.D.Z.); (G.A.S.); (V.A.R.); (E.V.K.)
| | - Elena V. Kuligina
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue, 8, 630090 Novosibirsk, Russia; (N.S.V.); (M.A.D.); (Y.I.S.); (A.B.A.); (A.S.D.); (N.D.Z.); (G.A.S.); (V.A.R.); (E.V.K.)
| |
Collapse
|
|
3
|
Dsouza L, Pant A, Offei S, Priyamvada L, Pope B, Satheshkumar PS, Wang Z, Yang Z. Antiviral activities of two nucleos(t)ide analogs against vaccinia, mpox, and cowpox viruses in primary human fibroblasts. Antiviral Res 2023:105651. [PMID: 37270160 PMCID: PMC10234405 DOI: 10.1016/j.antiviral.2023.105651] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 05/21/2023] [Accepted: 05/31/2023] [Indexed: 06/05/2023]
Abstract
Many poxviruses are significant human and animal pathogens, including viruses that cause smallpox and mpox (formerly monkeypox). Identifying novel and potent antiviral compounds is critical to successful drug development targeting poxviruses. Here we tested two compounds, nucleoside trifluridine, and nucleotide adefovir dipivoxil, for antiviral activities against vaccinia virus (VACV), mpox virus (MPXV), and cowpox virus (CPXV) in physiologically relevant primary human fibroblasts. Both compounds potently inhibited the replication of VACV, CPXV, and MPXV (MA001 2022 isolate) in plaque assays. In our recently developed assay based on a recombinant VACV expressing secreted Gaussia luciferase, they both exhibited high potency in inhibiting VACV replication with EC50s in the low nanomolar range. In addition, both trifluridine and adefovir dipivoxil inhibited VACV DNA replication and downstream viral gene expression. Our results characterized trifluridine and adefovir dipivoxil as strong poxvirus antiviral compounds and further validate the VACV Gaussia luciferase assay as a highly efficient and reliable reporter tool for identifying poxvirus inhibitors. Given that both compounds are FDA-approved drugs, and trifluridine is already used to treat ocular vaccinia, further development of trifluridine and adefovir dipivoxil holds great promise in treating poxvirus infections, including mpox.
Collapse
Affiliation(s)
- Lara Dsouza
- Department of Veterinary Pathobiology, School of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX, USA
| | - Anil Pant
- Department of Veterinary Pathobiology, School of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX, USA
| | - Samuel Offei
- Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA
| | - Lalita Priyamvada
- Poxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Blake Pope
- Department of Veterinary Pathobiology, School of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX, USA
| | | | - Zhengqiang Wang
- Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA.
| | - Zhilong Yang
- Department of Veterinary Pathobiology, School of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX, USA.
| |
Collapse
|
|
4
|
Dsouza L, Pant A, Offei S, Priyamvada L, Pope B, Satheshkumar PS, Wang Z, Yang Z. Antiviral activities of two nucleos(t)ide analogs against vaccinia and mpox viruses in primary human fibroblasts. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.03.23.533943. [PMID: 36993701 PMCID: PMC10055413 DOI: 10.1101/2023.03.23.533943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 04/26/2023]
Abstract
Many poxviruses are significant human and animal pathogens, including viruses that cause smallpox and mpox. Identification of inhibitors of poxvirus replication is critical for drug development to manage poxvirus threats. Here we tested two compounds, nucleoside trifluridine and nucleotide adefovir dipivoxil, for antiviral activities against vaccinia virus (VACV) and mpox virus (MPXV) in physiologically relevant primary human fibroblasts. Both trifluridine and adefovir dipivoxil potently inhibited replication of VACV and MPXV (MA001 2022 isolate) in a plaque assay. Upon further characterization, they both conferred high potency in inhibiting VACV replication with half maximal effective concentrations (EC 50 ) at low nanomolar levels in our recently developed assay based on a recombinant VACV secreted Gaussia luciferase. Our results further validated that the recombinant VACV with Gaussia luciferase secretion is a highly reliable, rapid, non-disruptive, and simple reporter tool for identification and chracterization of poxvirus inhibitors. Both compounds inhibited VACV DNA replication and downstream viral gene expression. Given that both compounds are FDA-approved drugs, and trifluridine is used to treat ocular vaccinia in medical practice due to its antiviral activity, our results suggest that it holds great promise to further test trifluridine and adefovir dipivoxil for countering poxvirus infection, including mpox.
Collapse
Affiliation(s)
- Lara Dsouza
- Department of Veterinary Pathobiology, School of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA
| | - Anil Pant
- Department of Veterinary Pathobiology, School of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA
| | - Samuel Offei
- Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
| | - Lalita Priyamvada
- Poxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
| | - Blake Pope
- Department of Veterinary Pathobiology, School of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA
| | - Panayampalli S. Satheshkumar
- Poxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
- Correspondence: (SPS); (ZW); (ZY)
| | - Zhengqiang Wang
- Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
- Correspondence: (SPS); (ZW); (ZY)
| | - Zhilong Yang
- Department of Veterinary Pathobiology, School of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA
- Correspondence: (SPS); (ZW); (ZY)
| |
Collapse
|
|
5
|
Current and Perspective Sensing Methods for Monkeypox Virus. Bioengineering (Basel) 2022; 9:bioengineering9100571. [PMID: 36290539 PMCID: PMC9598380 DOI: 10.3390/bioengineering9100571] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Revised: 10/13/2022] [Accepted: 10/14/2022] [Indexed: 11/17/2022] Open
Abstract
The outbreak of the monkeypox virus (MPXV) in non-endemic countries is an emerging global health threat and may have an economic impact if proactive actions are not taken. As shown by the COVID-19 pandemic, rapid, accurate, and cost-effective virus detection techniques play a pivotal role in disease diagnosis and control. Considering the sudden multicountry MPXV outbreak, a critical evaluation of the MPXV detection approaches would be a timely addition to the endeavors in progress for MPXV control and prevention. Herein, we evaluate the current MPXV detection methods, discuss their pros and cons, and provide recommended solutions to the problems. We review the traditional and emerging nucleic acid detection approaches, immunodiagnostics, whole-particle detection, and imaging-based MPXV detection techniques. The insights provided in this article will help researchers to develop novel techniques for the diagnosis of MPXV.
Collapse
|
|
6
|
Lothert K, Pagallies F, Eilts F, Sivanesapillai A, Hardt M, Moebus A, Feger T, Amann R, Wolff MW. A scalable downstream process for the purification of the cell culture-derived Orf virus for human or veterinary applications. J Biotechnol 2020; 323:221-230. [PMID: 32860824 DOI: 10.1016/j.jbiotec.2020.08.014] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Revised: 08/06/2020] [Accepted: 08/23/2020] [Indexed: 12/11/2022]
Abstract
The large demand for safe and efficient viral vector-based vaccines and gene therapies against both inherited and acquired diseases accelerates the development of viral vectors. One outstanding example, the Orf virus, has a wide range of applications, a superior efficacy and an excellent safety profile combined with a reduced pathogenicity compared to other viral vectors. However, besides these favorable attributes, an efficient and scalable downstream process still needs to be developed. Recently, we screened potential chromatographic stationary phases for Orf virus purification. Based on these previous accomplishments, we developed a complete downstream process for the cell culture-derived Orf virus. The described process comprises a membrane-based clarification step, a nuclease treatment, steric exclusion chromatography, and a secondary chromatographic purification step using Capto® Core 700 resin. The applicability of this process to a variety of diverse Orf virus vectors was shown, testing two different genotypes. These studies render the possibility to apply the developed downstream scheme for both genotypes, and lead to overall virus yields of about 64 %, with step recoveries of >70 % for the clarification, and >90 % for the chromatography train. Protein concentrations of the final product are below the detection limits, and the final DNA concentration of about 1 ng per 1E + 06 infective virus units resembles a total DNA depletion of 96-98 %.
Collapse
Affiliation(s)
- Keven Lothert
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen (THM), Giessen, Germany
| | - Felix Pagallies
- Department of Immunology, University of Tuebingen, Tuebingen, Germany
| | - Friederike Eilts
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen (THM), Giessen, Germany
| | - Arabi Sivanesapillai
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen (THM), Giessen, Germany
| | - Martin Hardt
- Imaging Unit, Biomedical Research Centre Seltersberg, Justus Liebig University, Giessen, Germany
| | - Anna Moebus
- Imaging Unit, Biomedical Research Centre Seltersberg, Justus Liebig University, Giessen, Germany
| | - Thomas Feger
- Department of Immunology, University of Tuebingen, Tuebingen, Germany
| | - Ralf Amann
- Department of Immunology, University of Tuebingen, Tuebingen, Germany
| | - Michael W Wolff
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen (THM), Giessen, Germany; Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Giessen, Germany.
| |
Collapse
|
|
7
|
Fay PC, Cook CG, Wijesiriwardana N, Tore G, Comtet L, Carpentier A, Shih B, Freimanis G, Haga IR, Beard PM. Madin-Darby bovine kidney (MDBK) cells are a suitable cell line for the propagation and study of the bovine poxvirus lumpy skin disease virus. J Virol Methods 2020; 285:113943. [PMID: 32707050 PMCID: PMC7561597 DOI: 10.1016/j.jviromet.2020.113943] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Revised: 07/14/2020] [Accepted: 07/19/2020] [Indexed: 11/30/2022]
Abstract
LSDV replicates to high titers (approximately 1 × 107 PFU/mL) in MDBK cells. LSDV forms foci-like poxviral plaques in MDBK cells. A plaque-reduction neutralisation test was developed for LSDV antibody quantitation. A method for purification of LSDV genomic DNA was optimized.
Lumpy skin disease virus (LSDV) is a poxvirus that causes systemic disease in cattle, resulting in substantial economic loss to affected communities. LSDV is a rapidly emerging pathogen of growing global concern that recently spread from Africa and the Middle East into Europe and Asia, impacting the cattle population in these regions. An increase in research efforts into LSDV is required to address key knowledge gaps, however this is hampered by lack of suitable cell lines on which to propagate and study the virus. In this work we describe the replication and spread of LSDV on Madin-Darby bovine kidney (MDBK) cells, and the formation of foci-type poxvirus plaques by LSDV on MDBK cells. Methods utilising MDBK cells to quantify neutralising antibodies to LSDV, and to purify LSDV genomic DNA suitable for short read sequencing are described. These research methods broaden the tools available for LSDV researchers and will facilitate the gathering of evidence to underpin the development of LSD control and prevention programmes.
Collapse
Affiliation(s)
- Petra C Fay
- The Pirbright Institute, Ash Rd, Surrey, GU24 0NF, UK
| | | | | | - Gessica Tore
- The Pirbright Institute, Ash Rd, Surrey, GU24 0NF, UK
| | - Loic Comtet
- IDvet, 310 Rue Louis Pasteur, 34790, Grabels, France
| | | | - Barbara Shih
- The Roslin Institute / Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, UK
| | | | - Ismar R Haga
- The Pirbright Institute, Ash Rd, Surrey, GU24 0NF, UK
| | - Philippa M Beard
- The Pirbright Institute, Ash Rd, Surrey, GU24 0NF, UK; The Roslin Institute / Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, UK.
| |
Collapse
|
|
8
|
Americo JL, Earl PL, Moss B. Droplet digital PCR for rapid enumeration of viral genomes and particles from cells and animals infected with orthopoxviruses. Virology 2017; 511:19-22. [PMID: 28802157 PMCID: PMC5623639 DOI: 10.1016/j.virol.2017.08.005] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Revised: 08/01/2017] [Accepted: 08/02/2017] [Indexed: 11/23/2022]
Abstract
Droplet digital polymerase chain reaction (ddPCR) was adapted for quantifying the number of orthopoxviral genomes in purified virus samples, infected cell lysates and tissues of infected animals. In contrast to the more commonly used qPCR, the newer ddPCR provides absolute numbers of DNA copies in samples without need for standard curves and has the ability to detect rare mutants in a population. The genome/infectious unit ratio for several sucrose gradient-purified orthopoxviruses varied from 5 to 10, which correlated well with values obtained using the Virocyt, a dedicated fluorescence flow cytometer. By employing a nuclease step to digest unencapsulated DNA, the genome/infectious unit ratios of virus in crude cell lysates approached that of purified virus particles. The speed, accuracy, sensitivity, and dynamic range of less than one to millions of infectious units in a sample make this semi-automated method well suited to a variety of laboratory, animal and clinical studies.
Collapse
Affiliation(s)
- Jeffrey L Americo
- Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States
| | - Patricia L Earl
- Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States
| | - Bernard Moss
- Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States.
| |
Collapse
|